4DMedical Ltd (AU:4DX)
ASX:4DX
Top Page
4DMedical Ltd
(Sydney:4DX)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$6.00
â–¼(-4.46% Downside)
Action:ReiteratedDate:03/26/26
The score is held down primarily by weak financial performance (declining revenue, persistent losses, and negative cash flows). This is partially offset by strong technical momentum with price well above key moving averages and a positive MACD, while valuation remains unattractive due to the negative P/E and no dividend support in the provided data.
Positive Factors
Proprietary XV Technology platform
4DMedical’s XV Technology is a specialized, clinically oriented imaging platform that generates quantitative functional lung metrics from CT scans. That proprietary capability supports differentiation, potential clinical adoption and licensing, creating a durable competitive moat versus generic imaging tools.
Negative Factors
Declining revenue trend
A year-over-year revenue decline signals adoption or commercial execution issues. Persistent top-line contraction undermines operating leverage and makes it harder to recover fixed R&D and commercialization costs, extending the timeline to sustainable profitability unless adoption reverses.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary XV Technology platform
4DMedical’s XV Technology is a specialized, clinically oriented imaging platform that generates quantitative functional lung metrics from CT scans. That proprietary capability supports differentiation, potential clinical adoption and licensing, creating a durable competitive moat versus generic imaging tools.
Read all positive factors
4DMedical Ltd (4DX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$3.61B
Dividend YieldN/A
Average Volume (3M)10.77M
Price to Earnings (P/E)―
Beta (1Y)2.05
Revenue Growth55.91%
EPS Growth22.60%
CountryAU
Employees145
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding574,357,600
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.75Price Target Upside-40.29% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
4DMedical Ltd Business Overview & Revenue Model
Company Description
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung venti...
How the Company Makes Money
4DMedical generates revenue primarily by selling and licensing its lung imaging software to healthcare providers and related institutions, and by providing associated implementation and support services. Key revenue streams include: (1) Software l...
4DMedical Ltd Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
45
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.33M | 5.85M | 3.75M | 718.58K | 1.05M | 216.98K |
| Gross Profit | -17.18M | 5.39M | 3.52M | 684.43K | 280.62K | 125.13K |
| EBITDA | -35.46M | -45.82M | -31.86M | -33.74M | -35.25M | -18.04M |
| Net Income | -159.59M | -30.07M | -35.98M | -31.46M | -24.59M | -21.42M |
Balance Sheet | ||||||
| Total Assets | 139.55M | 94.81M | 120.02M | 92.92M | 74.31M | 92.64M |
| Cash, Cash Equivalents and Short-Term Investments | 56.76M | 6.88M | 30.61M | 69.58M | 51.11M | 80.88M |
| Total Debt | 6.42M | 4.31M | 5.12M | 5.14M | 6.24M | 1.69M |
| Total Liabilities | 167.95M | 30.58M | 49.09M | 21.46M | 14.80M | 9.28M |
| Stockholders Equity | -28.40M | 64.24M | 70.93M | 71.46M | 59.51M | 83.36M |
Cash Flow | ||||||
| Free Cash Flow | -22.99M | -34.56M | -31.17M | -23.38M | -28.35M | -15.25M |
| Operating Cash Flow | -22.82M | -34.48M | -30.87M | -22.65M | -25.27M | -14.52M |
| Investing Cash Flow | -1.62M | -1.62M | -40.04M | -1.61M | -3.50M | -580.45K |
| Financing Cash Flow | 75.41M | 12.37M | 31.94M | 42.73M | -995.47K | 87.55M |
4DMedical Ltd Technical Analysis
Positive
6.28
Price Trends
4.07
Positive
3.31
Positive
2.16
Positive
Market Momentum
0.49
Negative
77.61
Negative
83.92
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:4DX, the sentiment is Positive. The current price of 6.28 is above the 20-day moving average (MA) of 4.51, above the 50-day MA of 4.07, and above the 200-day MA of 2.16, indicating a bullish trend. The MACD of 0.49 indicates Negative momentum. The RSI at 77.61 is Negative, neither overbought nor oversold. The STOCH value of 83.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:4DX.
4DMedical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$196.92M | -47.06 | -3.80% | ― | 16.93% | 76.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$3.61B | -3.16 | -890.76% | ― | 55.91% | 22.60% | |
45 Neutral | AU$30.58M | -1.41 | -165.13% | ― | 23.31% | -17.35% | |
44 Neutral | AU$90.60M | -6.27 | -54.48% | ― | 34.20% | -23.90% | |
44 Neutral | AU$144.05M | -10.00 | -70.29% | ― | ― | -257.32% | |
41 Neutral | AU$39.93M | -2.66 | -180.06% | ― | -14.25% | -22.83% |
* Healthcare Sector Average
AU:4DX
4DMedical Ltd
6.28
6.01
2225.93%
AU:IPD
Impedimed Limited
0.02
-0.03
-63.41%
AU:CYC
Cyclopharm Limited
0.75
-0.40
-34.78%
AU:MX1
Micro-X Ltd.
0.06
>-0.01
-8.33%
AU:ARX
Aroa Biosurgery Ltd
0.57
0.15
35.71%
AU:EMV
EMvision Medical Devices Ltd.
1.55
-0.57
-26.89%
4DMedical Ltd Corporate Events
4DMedical wins Mayo Clinic deployment in push to make CT:VQ lung imaging standard of care
Mar 24, 2026
4DMedical has secured deployment of its CT:VQ ventilation-perfusion imaging technology at Mayo Clinic, the top-ranked U.S. hospital, marking a major endorsement of its platform by one of the most influential healthcare institutions globally. The i...
4DMedical Issues New Shares Under Incentive Plan and Confirms Regulatory Compliance
Mar 18, 2026
4DMedical has issued 485,976 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan, expanding its share base in line with previously established employee and executive remuneration structures. The company ...
4DMedical Seeks ASX Quotation for Additional Ordinary Shares
Mar 18, 2026
4DMedical has applied for quotation on the ASX of 485,976 new fully paid ordinary shares, to be issued on 18 March 2026 under the ticker 4DX. The move modestly increases the company’s listed share capital and reflects the conversion of exist...
4DMedical Seeks ASX Quotation for Additional Ordinary Shares
Mar 13, 2026
4DMedical Ltd has applied to the ASX for quotation of an additional 87,546 ordinary fully paid shares, issued in two tranches on March 6 and March 13, 2026. The new securities stem from the exercise or conversion of existing options or other conve...
4DMedical Added to All Ordinaries in S&P Dow Jones March Rebalance
Mar 10, 2026
4DMedical Limited has been added to the SP/ASX All Ordinaries Index as part of SP Dow Jones Indices’ March 2026 quarterly rebalance, effective before the market opens on 23 March 2026. The reshuffle reverses earlier plans affecting African G...
4DMedical Joins S&P/ASX 300 in Broad Rebalance of Australian Indices
Mar 6, 2026
SP Dow Jones Indices has announced its March 2026 quarterly rebalance of the SP/ASX suite, shifting membership across the 20, 50, 100, 200, and 300 benchmarks effective before trading on March 23. The reshuffle reflects evolving market capitalisat...
4DMedical directors boost equity stakes as respiratory imaging portfolio expands
Mar 4, 2026
4DMedical Limited, a global medtech company specialising in AI-enhanced respiratory imaging, develops and commercialises software solutions such as XV Lung Ventilation Analysis Software, CT LVAS and CT:VQ, all delivered through a SaaS model for se...
4DMedical Issues New Shares Under Long-Term Incentive Plan, Confirms Regulatory Compliance
Mar 4, 2026
4DMedical has issued 1,583,776 fully paid ordinary shares following the exercise of options and restricted stock units under its Long Term Incentive Plan, with the issuance recorded in an Appendix 2A lodged with the ASX. The company has confirmed ...
4DMedical Seeks ASX Quotation for 1.58 Million New Shares
Mar 4, 2026
4DMedical Ltd has applied for quotation on the ASX of 1,583,776 new fully paid ordinary shares issued on 26 February 2026, following the exercise or conversion of existing options or other convertible securities. The additional shares will increas...
4DMedical Seeks ASX Quotation for Additional Ordinary Shares
Feb 27, 2026
4DMedical Ltd has applied to the ASX for quotation of 9,070 new fully paid ordinary shares under its ticker 4DX. The securities, issued on 23 February 2026 following the exercise or conversion of existing instruments, represent a minor increase to...
4DMedical Seeks ASX Quotation for 2 Million New Shares
Feb 20, 2026
4DMedical has applied to the ASX for quotation of 2,000,000 additional ordinary fully paid shares, issued on 13 February 2026 following the exercise of options or conversion of other securities. The move modestly increases the company’s free...
4DMedical Defends ASX Disclosure on Stanford Deal and Global Rollout
Jan 30, 2026
4DMedical has defended the adequacy of its disclosures to the ASX regarding its expanded agreement with Stanford University and additional hospital deployments in Brazil, arguing that the strategic significance of these deals lies in advancing its...
4DMedical Secures Commercial CT:VQ Deployment at University of Chicago Medicine
Jan 30, 2026
4DMedical has expanded its long-standing partnership with University of Chicago Medicine to include the commercial deployment of its CT:VQ lung imaging solution, adding an initial package of prepaid scans to accelerate clinical use at one of the U...
4DMedical Directors Lift Net Shareholdings Following Option Exercises
Jan 22, 2026
4DMedical has disclosed changes in the equity interests of three directors following a recent capital placement, detailing option exercises and share movements that modestly increase insider ownership. Chief executive Andreas Fouras and director J...
4DMedical Options Lapse, Simplifying Capital Structure
Jan 22, 2026
4DMedical Ltd has announced the expiry of 636,576 unexercised options (ASX code 4DXAT) with an exercise price of $0.79, which ceased on 17 January 2026. The lapse of these options, which did not convert into ordinary shares, results in a modest si...
4DMedical Seeks ASX Quotation for Over 6.1 Million New Shares
Jan 22, 2026
4DMedical Ltd has applied to the ASX for quotation of a total of 6,117,580 new ordinary fully paid shares, issued on 15 and 16 January 2026, under its ticker 4DX. The newly quoted securities arise from the exercise or conversion of existing option...
4DMedical Issues Over 20 Million New Shares Under Cleansing Notice
Jan 21, 2026
4DMedical Limited has issued 20,806,185 fully paid ordinary shares without a disclosure document, relying on provisions of the Corporations Act that allow such an issue by a compliant disclosing entity. The company confirmed it has met its continu...
4DMedical Seeks ASX Quotation for 20.8 Million New Shares
Jan 21, 2026
4DMedical Limited has applied to the ASX for quotation of 20,806,185 new fully paid ordinary shares (ASX code: 4DX), with an issue date of 22 January 2026. The move will expand the company’s quoted share base and may provide additional liqui...
4DMedical Outlines Business in New Investor Presentation with Strict Offer Disclaimers
Jan 18, 2026
4DMedical Limited has released an investor presentation dated 19 January 2026, providing a high-level overview of its business, group structure and activities, while emphasising that the material is informational, incomplete and subject to change....
4DMedical Seeks ASX Quotation for Over 6.1 Million New Shares
Jan 16, 2026
4DMedical Limited has applied to the ASX for quotation of a total of 6,136,176 new fully paid ordinary shares, issued on various dates between 6 and 16 January 2026, following the exercise or conversion of options or other convertible securities. ...
4DMedical Plans Placement of Over 20.8 Million New Shares
Jan 14, 2026
4DMedical Limited has announced a proposed placement of up to 20,806,185 new fully paid ordinary shares, with the issue expected to take place on 22 January 2026. The capital raising signals the company’s intention to strengthen its balance ...
4DMedical Raises $150m to Accelerate U.S. Push for CT:VQ Lung Imaging
Jan 14, 2026
4DMedical has secured $150 million in firm commitments through a single-tranche institutional placement at $3.80 per share, cornerstoned by global long-only institutional investors and strongly supported by existing shareholders, with overall dilu...
4DMedical Seeks Trading Halt Ahead of Planned Capital Raising
Jan 12, 2026
4DMedical Limited has requested and been granted a trading halt on its ordinary shares on the ASX from the start of trading on 13 January 2026, expected to last until trading resumes on 15 January 2026 or until a further announcement is made. The ...
4DMedical Raises $1.38m Through Underwritten Option Share Issue
Jan 11, 2026
4DMedical has issued 834,103 fully paid ordinary shares under an option underwriting agreement with Bell Potter Securities to cover unexercised 4DXO listed options that expired on 31 December 2025, raising approximately $1.38 million before costs ...
4DMedical to List 834,103 Shortfall Shares on ASX
Jan 9, 2026
4DMedical Limited, listed on the ASX under the code 4DX, has lodged an application for quotation of additional fully paid ordinary shares. The company will have 834,103 new ordinary shares quoted on the ASX, representing shortfall shares issued up...
4DMedical Adds UC San Diego Health as Fourth Major U.S. Academic Adopter of CT:VQ
Jan 6, 2026
4DMedical has secured UC San Diego Health, one of the top-ranked U.S. centres for pulmonology and lung surgery, as the fourth major academic medical centre to deploy its CT:VQ respiratory imaging solution for clinical use. Under an introductory pr...
4DMedical Seeks ASX Quotation for Shares Issued on Option Conversion
Jan 2, 2026
4DMedical Limited has applied to the ASX for quotation of new fully paid ordinary shares issued following the exercise or conversion of existing options or other convertible securities. The securities, which were issued on 2 January 2026, represen...
4DMedical Seeks Quotation of 394,446 New Shares on ASX
Jan 2, 2026
4DMedical Ltd has applied to the ASX for quotation of 394,446 new fully paid ordinary shares under its 4DX ticker. The additional securities, issued on 2 January 2026 following the exercise or conversion of existing options or other convertible se...
4DMedical Names Long-Serving Director Julian Sutton as CFO to Drive Global Scale-Up
Jan 1, 2026
4DMedical has strengthened its leadership team by appointing long-serving non-executive director and early investor Julian Sutton as Chief Financial Officer and Executive Director, formalising his strategic role after years of involvement in capit...
4DMedical Seeks ASX Quotation for Shares Issued on Option Conversion
Dec 31, 2025
4DMedical Limited has applied to the ASX for quotation of a new batch of fully paid ordinary shares issued following the exercise of options or conversion of other convertible securities. The securities, which were issued on 30 December 2025, repr...
4DMedical Seeks ASX Quotation for 144,307 New Shares
Dec 31, 2025
4DMedical Limited, listed on the ASX under the code 4DX, has applied for quotation of additional fully paid ordinary shares. The filing indicates that 144,307 new ordinary shares were issued on 30 December 2025, likely following the exercise of op...
4DMedical Seeks ASX Quotation for Shares Issued on Option Conversion
Dec 29, 2025
4DMedical Limited has lodged an Appendix 2A with the ASX applying for quotation of new fully paid ordinary shares that have been issued following the exercise or conversion of existing options or other convertible securities. The securities, which...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.